Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 10 versus KENALOG 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 10 versus KENALOG 40.
KENALOG-10 vs KENALOG-40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also stabilizes lysosomal membranes and inhibits fibroblast proliferation.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; suppresses cytokine production, inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes lysosomal membranes.
Intra-articular, intrabursal, or soft tissue injection: 10-40 mg (0.25-1 mL of 10 mg/mL) for large joints; 10 mg (0.25 mL) for small joints; repeat every 3-4 weeks if needed. Intralesional: 10-40 mg (0.25-1 mL) per lesion; maximum 1 mL per injection site; repeat every 1-2 weeks.
Intra-articular injection: 10-40 mg for large joints, 5-15 mg for medium joints, 2.5-5 mg for small joints. Intralesional injection: 2.5-5 mg per lesion. Intramuscular injection: 40-80 mg once monthly. Not for IV or subcutaneous use.
None Documented
None Documented
Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Terminal elimination half-life is approximately 2 to 3 hours after IV administration, but due to the triamcinolone acetonide suspension formulation, the effective half-life following intramuscular or intra-articular administration is prolonged to 2-3 weeks due to slow dissolution from the injection site.
Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites. Less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 15-20% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid